LeonaBio Gets $20 Price Target Ahead of June Pipeline Test
• Piper Sandler launched coverage on LeonaBio with an overweight rating and a $20 price target. Analyst Kelsey Goodwin is the lead on the name.• LeonaBio said it’s set to present ATH-1105 for ALS on June 3, and will join a trials panel in oncology on June 24.• Shares last traded at $9.81, up 1.45%, on volume a little above 51,000. Piper Sandler started coverage on LeonaBio Inc. with an overweight rating and a $20 target, giving the Nasdaq-listed biotech a new boost this week. The call comes ahead of LeonaBio’s scheduled medical-meeting appearances in June.